BMO Capital Markets set a $84.00 target price on AbbVie (NYSE:ABBV) in a research note issued to investors on Thursday. The brokerage currently has a hold rating on the stock.

ABBV has been the topic of several other reports. Leerink Swann set a $106.00 price objective on AbbVie and gave the company a buy rating in a report on Tuesday, December 5th. Argus raised their price objective on AbbVie from $90.00 to $110.00 and gave the company a buy rating in a report on Friday, September 29th. UBS Group lowered AbbVie from a buy rating to a neutral rating and raised their price objective for the company from $79.00 to $92.00 in a report on Monday, September 25th. SunTrust Banks reissued a buy rating and issued a $95.00 price objective on shares of AbbVie in a report on Wednesday, September 13th. Finally, Piper Jaffray Companies reaffirmed a buy rating and issued a $100.00 price target on shares of AbbVie in a research note on Friday, September 15th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $100.94.

Shares of AbbVie (ABBV) opened at $100.34 on Thursday. The company has a market capitalization of $160,185.78, a PE ratio of 24.41, a P/E/G ratio of 1.20 and a beta of 1.52. AbbVie has a 1-year low of $59.27 and a 1-year high of $101.28. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.39 by $0.02. The firm had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. AbbVie’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the company earned $1.21 earnings per share. analysts predict that AbbVie will post 5.54 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.83%. AbbVie’s payout ratio is currently 69.10%.

In related news, insider Henry O. Gosebruch sold 18,300 shares of AbbVie stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the transaction, the insider now owns 81,287 shares in the company, valued at $7,360,537.85. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Timothy J. Richmond sold 87,040 shares of AbbVie stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $98.45, for a total value of $8,569,088.00. Following the transaction, the senior vice president now owns 113,118 shares in the company, valued at approximately $11,136,467.10. The disclosure for this sale can be found here. Insiders sold 494,676 shares of company stock worth $47,237,938 over the last ninety days. Corporate insiders own 0.23% of the company’s stock.

A number of institutional investors have recently made changes to their positions in ABBV. Bristlecone Advisors LLC purchased a new stake in AbbVie in the third quarter valued at $113,000. Acropolis Investment Management LLC purchased a new stake in AbbVie in the second quarter valued at $106,000. Ffcm LLC raised its position in AbbVie by 167.2% in the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after purchasing an additional 963 shares during the period. Hudock Capital Group LLC raised its position in AbbVie by 109.5% in the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after purchasing an additional 806 shares during the period. Finally, Hershey Trust Co. purchased a new stake in AbbVie in the third quarter valued at $139,000. Hedge funds and other institutional investors own 69.19% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “AbbVie (ABBV) Given a $84.00 Price Target at BMO Capital Markets” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/15/abbvie-abbv-given-a-84-00-price-target-at-bmo-capital-markets.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related stocks with our FREE daily email newsletter.